GW&K Investment Management LLC Boosts Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

GW&K Investment Management LLC grew its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 34.9% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,863,987 shares of the medical device company's stock after acquiring an additional 740,499 shares during the quarter. GW&K Investment Management LLC owned 4.30% of Tandem Diabetes Care worth $54,874,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of TNDM. NBC Securities Inc. acquired a new position in Tandem Diabetes Care during the first quarter worth about $37,000. State of Wyoming grew its holdings in shares of Tandem Diabetes Care by 95.9% during the fourth quarter. State of Wyoming now owns 2,996 shares of the medical device company's stock worth $108,000 after purchasing an additional 1,467 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Tandem Diabetes Care by 102.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,902 shares of the medical device company's stock valued at $141,000 after acquiring an additional 1,977 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in Tandem Diabetes Care in the first quarter valued at approximately $205,000. Finally, Cibc World Markets Corp bought a new stake in Tandem Diabetes Care in the fourth quarter valued at approximately $221,000.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Stifel Nicolaus cut their price target on Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Canaccord Genuity Group upped their target price on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a "buy" rating in a research report on Thursday, May 1st. Wells Fargo & Company lowered their target price on Tandem Diabetes Care from $22.00 to $20.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 1st. Citigroup reaffirmed a "sell" rating and set a $14.00 target price (down from $24.00) on shares of Tandem Diabetes Care in a research report on Wednesday, July 9th. Finally, Mizuho initiated coverage on Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 target price on the stock. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $32.71.

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM traded down $0.14 during trading hours on Monday, reaching $14.63. 1,411,985 shares of the stock traded hands, compared to its average volume of 1,505,883. The company has a debt-to-equity ratio of 1.99, a quick ratio of 1.81 and a current ratio of 2.30. The company's 50-day simple moving average is $19.61 and its two-hundred day simple moving average is $23.58. Tandem Diabetes Care, Inc. has a 52-week low of $14.32 and a 52-week high of $47.60.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last posted its earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The business had revenue of $234.42 million for the quarter, compared to analysts' expectations of $220.19 million. During the same period last year, the firm posted ($0.65) earnings per share. Tandem Diabetes Care's quarterly revenue was up 22.3% on a year-over-year basis. Equities analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.